Clal Insurance Enterprises Holdings Ltd Sells 876,000 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Clal Insurance Enterprises Holdings Ltd lessened its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 2.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 31,486,683 shares of the company’s stock after selling 876,000 shares during the period. Teva Pharmaceutical Industries comprises 4.8% of Clal Insurance Enterprises Holdings Ltd’s investment portfolio, making the stock its 4th biggest holding. Clal Insurance Enterprises Holdings Ltd’s holdings in Teva Pharmaceutical Industries were worth $633,456,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the stock. Cromwell Holdings LLC boosted its holdings in Teva Pharmaceutical Industries by 40.3% during the 3rd quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock worth $44,000 after acquiring an additional 629 shares during the last quarter. Advisors Asset Management Inc. purchased a new position in Teva Pharmaceutical Industries during the second quarter worth about $41,000. Rothschild Investment LLC grew its position in Teva Pharmaceutical Industries by 97.0% in the 3rd quarter. Rothschild Investment LLC now owns 2,738 shares of the company’s stock worth $55,000 after purchasing an additional 1,348 shares in the last quarter. JFS Wealth Advisors LLC increased its stake in Teva Pharmaceutical Industries by 257.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 2,778 shares of the company’s stock valued at $56,000 after buying an additional 2,000 shares during the last quarter. Finally, LRI Investments LLC increased its stake in Teva Pharmaceutical Industries by 246.0% in the 3rd quarter. LRI Investments LLC now owns 2,813 shares of the company’s stock valued at $57,000 after buying an additional 2,000 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Insider Activity

In other news, Director Roberto Mignone sold 77,400 shares of the business’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $30.24, for a total transaction of $2,340,576.00. Following the transaction, the director directly owned 367,600 shares of the company’s stock, valued at approximately $11,116,224. The trade was a 17.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Mark Sabag sold 216,892 shares of the firm’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $28.73, for a total value of $6,231,307.16. Following the completion of the sale, the insider directly owned 52,828 shares of the company’s stock, valued at $1,517,748.44. The trade was a 80.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 422,060 shares of company stock valued at $12,254,965. 0.49% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Stock Up 0.2%

TEVA opened at $33.85 on Friday. Teva Pharmaceutical Industries Ltd. has a 12 month low of $12.47 and a 12 month high of $37.35. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 1.89. The business’s 50-day moving average price is $32.94 and its 200-day moving average price is $25.68. The company has a market cap of $38.92 billion, a P/E ratio of 28.21, a P/E/G ratio of 11.30 and a beta of 0.70.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The business had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.36 billion. During the same period in the previous year, the firm earned $0.71 EPS. The business’s quarterly revenue was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, equities analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on TEVA shares. Scotiabank raised their target price on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research report on Thursday, January 29th. Barclays raised their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the stock an “overweight” rating in a report on Friday, January 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, January 21st. Bank of America raised their price target on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Finally, The Goldman Sachs Group increased their price objective on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a report on Monday, February 9th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $37.56.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.